Recent News

• 10.01.2025 - NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
• 10.01.2025 - NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
• 09.30.2025 - NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
• 09.30.2025 - NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
• 09.29.2025 - NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
• 09.29.2025 - NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
• 09.18.2025 - New Phase 1 Results In Metastatic Melanoma
• 09.18.2025 - New Phase 1 Results In Metastatic Melanoma
• 09.17.2025 - NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
• 09.17.2025 - NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

Recent Filings

• 10.01.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.01.2025 - EX-99.1 EX-99.1
• 09.30.2025 - EX-99.1 EX-99.1
• 09.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.30.2025 - EX-99.1 EX-99.1
• 09.17.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.17.2025 - EX-99.1 EX-99.1